Yakuchinone B Ameliorates DSS-Induced Colitis by Modulating the Gut Microbiota-Metabolite Axis
Nutrients · 12.08.2026 · 18 (16) · 2628
DOI: 10.3390/nu18162628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 12.08.2026. Verfasst von Yang Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Technology, Hunan Agricultural University, Changsha 410128, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Colitis, Anti-Inflammatory Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background/Objectives: Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal disorder characterized by intestinal inflammation and gut microbiota dysbiosis, but current therapies remain limited by adverse effects and suboptimal long-term efficacy.
Methods
Here, using a dextran sulfate sodium (DSS)-induced mouse model of IBD-like colitis, we investigated the protective effects of Yakuchinone B (YB)—a diarylheptanoid derived from Alpinia oxyphylla with reported anti-inflammatory and antioxidant activities—against inflammatory bowel disease (IBD).
Results
YB supplementation significantly alleviated colitis symptoms, as evidenced by reduced body weight loss, lower disease activity index scores, attenuated colonic shortening, and ameliorated histopathological damage. YB also decreased the colonic and serum levels of TNF-α, IL-1β, and IL-6. Microbiome profiling showed that YB restored gut microbial diversity and reshaped microbial composition, with increased abundances of Alistipes and Duncaniella and reduced overgrowth of Akkermansia. Untargeted metabolomics revealed that YB modulated colitis-associated pathways, including purine metabolism, alanine, aspartate, and glutamate metabolism, and steroid hormone biosynthesis. Targeted analysis further showed that YB increased acetate, propionate, and butyrate levels.
Conclusions
These results collectively suggest that YB ameliorates DSS-induced colitis by attenuating inflammation, associated with modulation of the gut microbiota-host metabolism axis, and promoting short-chain fatty acid production, supporting its potential as a promising functional dietary candidate for IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science and Technology, Hunan Agricultural University, Changsha 410128, China.
- Hunan Engineering Research Center for Nutrition, Health and Deep Processing of Rapeseed Oil, Hunan Agricultural University, Changsha 410128, China.
- Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA.
- College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha 410128, China.
ORCID-Profile: Hang Xiao, Zhonghai Tang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Peng, W., Fan, W., Xiao, H., Guo, S., Tang, Z., & Qin, J. (2026). Yakuchinone B Ameliorates DSS-Induced Colitis by Modulating the Gut Microbiota-Metabolite Axis. Nutrients, 18(16), 2628. https://doi.org/10.3390/nu18162628
Vancouver
Wang Y, Peng W, Fan W, Xiao H, Guo S, Tang Z, et al. Yakuchinone B Ameliorates DSS-Induced Colitis by Modulating the Gut Microbiota-Metabolite Axis. Nutrients. 2026;18(16):2628. doi:10.3390/nu18162628
BibTeX
@article{Wang2026,
author = {Wang, Yang and Peng, Wang and Fan, Wei and Xiao, Hang and Guo, Shiyin and Tang, Zhonghai and Qin, Jingping},
title = {Yakuchinone B Ameliorates DSS-Induced Colitis by Modulating the Gut Microbiota-Metabolite Axis},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {16},
pages = {2628},
doi = {10.3390/nu18162628}
}
EUVIMED